Become a member Register now
Coming soon: xMas 
Special
Special
Special
|
DGAP-News: MPH Health Care AG
/ Key word(s): 9 Month figures/Monthly Figures
MPH Health Care AG: Preliminary IFRS third quarter 2020 results published. Equity (net asset value) amounts to € 194.39 million. This corresponds to € 45.40 per share. Berlin, 27 November 2020: MPH Health Care AG (ISIN: DE000A0L1H32) announces preliminary IFRS results for the third quarter of 2020. Accordingly, the equity of the investment company as of 30 September 2020 amounts to 194.39 million euros (30 September 2019: 239.57 million euros). The net asset value (NAV) per share as of 30 September 2020 is 45.40 euros (30 September 2019: 55.96 euros). The preliminary IFRS net result for the first nine months of the 2020 financial year is EUR -77.25 million (30 September 2019: EUR -21.00 million). The reason for the net loss for the period is mainly due to the fair value measurement of the share prices of the investments on 30 September 2020 as of the reporting date compared to the share prices on 31 December 2019. The share prices of the MPH investment companies have fallen in the course of this year's turbulence on the stock markets and have not yet been able to reach their level of the previous year. "We are confident about the further development of our listed investments CR Capital Real Estate AG, M1 Kliniken AG despite this year's share price decline. The two direct investments M1 and CR are developing positively in operational terms. At HAEMATO - now an indirect investment - important measures to expand the product portfolio and increase earnings are also being implemented", says Patrick Brenske, member of the board of MPH. About MPH Health Care AG: MPH Health Care AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Contact:Patrick Brenske, Management Board Corporate Communications E-Mail: ir@mph-ag.de
27.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
| Language: | English |
| Company: | MPH Health Care AG |
| Grünauer Straße 5 | |
| 12557 Berlin | |
| Germany | |
| Phone: | 030 / 863 21 45 60 |
| Fax: | 030 / 863 21 45 69 |
| E-mail: | info@mph-ag.de |
| Internet: | www.mph-ag.de |
| ISIN: | DE000A289V03, DE000A289VT5 |
| WKN: | A289V0 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1150717 |
| End of News | DGAP News Service |
|
|
1150717 27.11.2020
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
